Oxilio announces start of its first clinical trial with OXL001
Oxilio has commenced first human subject dosing of OXL001. The product leverages the Quotient Sciences Translational Pharmaceutics® platform for drug development.
Emplicure AB Announce Completion of Phase I PK study for EMPLI03 with Quotient Sciences
Emplicure AB reported dosing in the first Phase I pharmacokinetic study for EMPLI03, intended for the treatment of moderate to severe pain. The program is supported by Quotient Sciences Translational Pharmaceutics® platform.
Quotient Sciences Completes Major Expansion of Drug Substance Manufacturing Facility
Quotient Sciences, the drug development and manufacturing accelerator, has completed the expansion of its drug substance manufacturing facility in Alnwick, UK. The £6 million project results in a state-of-the-art drug substance manufacturing capability that can deliver integrated support for customers from candidate selection through to early clinical development and beyond.
Oxilio and Quotient Sciences Announce Regulatory Approval for Oxilio’s OXL001 Development Program
Oxilio and Quotient Sciences announced an update on the development of Oxilio’s OXL001 product, which uses Quotient Sciences’ Translational Pharmaceutics® platform.
Quotient Sciences Completes Qualification of GastroPlus® PBPK Modeling Software
Quotient Sciences’ Modeling and Simulation (M&S) team has recently completed qualification of GastroPlus software for physiologically based pharmacokinetic (PBPK) modeling.